

## CORRECTION




# Correction: Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities

L. Y. Lin, L. M. Du, K. Cao, Y. Huang, P. F. Yu, L. Y. Zhang, F. Y. Li, Y. Wang and Y. F. Shi

© The Author(s), under exclusive licence to Springer Nature Limited 2026

*Oncogene* (2026) 45:663; <https://doi.org/10.1038/s41388-026-03678-z>

Correction to: *Oncogene* <https://doi.org/10.1038/onc.2016.131>, published online 02 May 2016

**Published**

Following publication of this article, an error was noted in the presentation of panels in Figure 3f, which illustrates the effect of a CCR2 inhibitor, RS504393, on blood CD11b+Ly6C<sup>high</sup> cells in mice inoculated with B16-F0 cells and TE-MSCs.

Specifically, in the bottom right panel the authors inadvertently used flow cytometry data from the B16-F0 + CCR2 inhibitor condition instead of the correct B16-F0 + TE-MSCs + CCR2 inhibitor data. The corrected figure is provided below.

The authors apologize for this error and any inconvenience it may have caused.

**Corrected**